Vijay V Upreti

21PUBLICATIONS
49CO-AUTHORS
Epidemiological modellingApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Apr 24, 2026
A Phase 1 Study Evaluating the Pharmacokinetics and Safety of Avacopan in Participants with End-Stage Kidney Disease on Hemodialysis.

|Apr 08, 2026
A phase 1/1b study of the BCMA-targeting bispecific T-cell engager pavurutamab for relapsed/refractory multiple myeloma.

Hans C Lee, Wouter J Plattel, Simon J Harrison

|Sep 05, 2025
Clinical Pharmacology Characterization of the First-In-Class Oncolytic Viral Therapy T-VEC in Adults and Pediatric Subjects.

Xinwen Zhang, Bhavya Balu, Po-Wei Chen

|Aug 06, 2025
Clinical Pharmacology Characterization and Dose Selection of Xaluritamig, a Next Generation XmAb® 2+1 T-Cell Engager, in Prostate Cancer Patients.

Jamie N Kuipers-Connarn, Arya Pourzanjani, Maitreyee Bose

|Oct 04, 2024
Oncology Combination Drug Development Strategies for Project Optimus.

Timothy A Yap, Julie Bullock, Susan Chong

|Sep 16, 2024
An Innovative Approach to Optimize First-In-Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T-Cell Engagers: Experience from A Solid Tumor Bispecific T-Cell Engager.

Di Zhou, Roman Kischel, Sabine Stienen

Pageof 4

Frequent Collaborators

2 joint publications

Johannes Kast

2 joint publications

Rajneet K Oberoi

2 joint publications

Karthik Venkatakrishnan

1 joint publications

Arya Pourzanjani